Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurosci Lett. 2015 Jan 1;584:276-81. doi: 10.1016/j.neulet.2014.10.039. Epub 2014 Nov 1.

Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats.

Author information

1
Department of Neurology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
2
Department of Neurology, Yale University School of Medicine, New Haven, USA.
3
Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan.
4
Department of Neurology, School of Medicine, Sapporo Medical University, Sapporo, Japan. Electronic address: shimoha@sapmed.ac.jp.

Erratum in

  • Neurosci Lett. 2015 Feb 5;587:5. Iwahara, Naoyuki [corrected to Iwahara, Naotoshi].

Abstract

To explore a novel therapy against Parkinson's disease (PD), we evaluated the therapeutic effects of human bone marrow-derived mesenchymal stem cells (hBM-MSCs), pluripotent stromal cells with secretory potential of various neurotrophic and anti-inflammatory factors, in a hemi-parkinsonian rat model. The unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were injected hBM-MSCs (1.0 × 10(7)cells) or PBS intravenously 16 days after lesioning. Administration of hBM-MSCs inhibited methamphetamine-stimulated rotational behavior at 7, 14, 21 and 28 days after transplantation. Immunohistochemical analysis also showed that number of TH-positive neurons in the substantia nigra pars compacta was significantly preserved in hBM-MSCs-transplanted rats compared to sham-operated rats, whereas the immunoreactivity of ionized calcium binding adaptor molecule 1 was markedly inhibited. In this study, we demonstrated the therapeutic effects of intravenous hBM-MSCs administration in parkinsonian model rats presenting distinct parkinsonian phenotype at 16 days after 6-OHDA lesioning. The favorable findings raise the possibility that hBM-MSCs could be a novel therapeutic option to promote survival of dopaminergic neurons in PD.

KEYWORDS:

6-Hydroxydopamine; Anti-inflammatory; Mesenchymal stem cell; Neuroprotection; Parkinson's disease

PMID:
25449872
DOI:
10.1016/j.neulet.2014.10.039
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center